NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Gritstone investors who were adversely affected by alleged securities fraud between March 9, 2023 and February 29, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/gritstone-lawsuit-su ...

Core Viewpoint - Levi & Korsinsky, LLP has initiated a class action securities lawsuit against Gritstone bio, Inc. due to alleged securities fraud impacting investors between March 9, 2023, and February 29, 2024 [6]. Group 1: Allegations Against Gritstone - The complaint alleges that Gritstone made false statements regarding its ability to launch the Phase 2b CORAL Study for its COVID-19 vaccine within the promised timeframe [4]. - It is claimed that Gritstone's inability to launch the study would hinder its ability to secure external funding, negatively affecting its balance sheet and cash position [4]. - The lawsuit asserts that Gritstone overstated its capability to develop and commercialize its products, leading to materially false and misleading public statements [4]. Group 2: Investor Information - Investors who suffered losses during the relevant timeframe have until August 6, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [5]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [5].

Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: March 9, 2023 to February 29, 2024 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of GRTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the ...

Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=88034&from=3 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company would be unable ...

Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=87811&from=4 DEADLINE: August 6, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/gritstone-loss-submission- ...

SO WHAT: If you purchased Gritstone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com WHAT TO DO NEXT: To join the Gritstone class action, go to https://rosenlegal.com/submit-form/? case_id=25945 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A ...

NEW YORK, June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=87100&from=4 CLASS PERIOD: March 9, 2023 to Feb ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"), of the important August 6, 2024 lead plaintiff deadline. DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Gritstone would be unable to launch the Phase 2b CORAL Study, a study comparing Gritstone's COVID-19 vacci ...

Core Viewpoint - Gritstone bio, Inc. is facing a class action lawsuit due to allegations of making false and misleading statements regarding its Phase 2b CORAL Study and its commercialization capabilities, which led to investor losses when the truth was revealed [1]. Group 1: Company Misconduct - The Company allegedly failed to launch its Phase 2b CORAL Study within the promised timeframe, impacting its ability to secure external funding [1]. - Gritstone overstated its ability to commercialize its products, leading to materially misleading public statements throughout the class period [1]. - Investors suffered damages when the market became aware of the true situation regarding Gritstone [1]. Group 2: Legal Actions - A class action has been filed on behalf of Gritstone investors who lost money, encouraging affected investors to contact the Portnoy Law Firm for assistance [2]. - The Portnoy Law Firm specializes in representing investors in claims related to corporate wrongdoing and has a history of recovering significant amounts for aggrieved investors [3]. - Investors who engaged with Gritstone shares between March 9, 2023, and February 29, 2024, are invited to discuss their legal rights and options for recovering losses [5].

Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Gritstone bio, Inc. (NASDAQ: GRTS) securities between March 9, 2023 and February 29, 2024. Gritstone is a clinical-stage biotechnology company that engages in developing vaccinebased immunotherapy candidates against cancer and infectious diseases. The Allegations: Robbins LLP is Investigating Allegations that Gritstone bio, Inc. (GRTS) Misled Investors Regarding the In ...